FMP
Antibe Therapeutics Inc.
ATE.TO
TSX
Inactive Equity
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.
0.295 CAD
0.035 (11.86%)
About
ceo
Mr. Alain Wilson M.B.A., MBA
sector
Healthcare
industry
Medical - Devices
website
https://www.antibethera.com
exchange
TSX
Description
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for a...
CIK
N/A
ISIN
CA0370255097
CUSIP
N/A
Address
15 Prince Arthur Avenue
Phone
416 922 3460
Country
CA
Employee
11
IPO Date
Jun 18, 2013
Summary
CIK
-
Exchange
TSX
Industry
Medical - Devices
Sector
Healthcare
CUSIP
-
ISIN
CA0370255097
Country
CA
Price
0.29
Beta
0.12
Volume Avg.
139.88k
Market Cap
15.53M
Shares
-
52-Week
0.15-1.23
DCF
0.13
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.84
P/B
-
Website
https://www.antibethera.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ATE.TO News
It looks like there's no news available.
